secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-255127
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech Q3 net loss $24.0M; Phase 3 melanoma trial on track for PFS in H1 2025
--------------------------------------------------------------------------------

- Net loss $24.0M for Q3 2024 vs $21.7M in Q3 2023; R&D expenses $20.2M up from $17.7M.
- Cash $80.2M as of Sep 30, 2024, down from $143.2M; cash runway into Q4 2025.
- Phase 3 trial IO102-IO103 + pembrolizumab in advanced melanoma: PFS primary endpoint expected H1 2025.
- Phase 2 SCCHN cohort met primary endpoint; data presented at ESMO and SITC.
- Plans BLA submission in 2025 and potential US launch in 2026; IND for IO112 in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312524255127/0001193125-24-255127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312524255127/d793963d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-255127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer